Kodiak Sciences Enrols First Patients In Global Phase 3 ALTO Trial Evaluating KSI-501 In Patients With Diabetic Macular Edema
Phase 3 ALTO trial designed to demonstrate superiority of KSI-501 versus aflibercept in patients with diabetic macular edemaPALO ALTO, Calif., Aug. 10, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a
Kodiak Sciences started testing a new eye medicine called KSI-501 in a big group of patients to see if it works better than a similar medicine that's already used. This is an important step forward, and we'll watch to see if the results show their medicine is actually better.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.